HLA-B27 is the strongest genetic risk factor for AxSpA positive in 90% of rAxSpA and 30-40% of PsA patients. B27 is an MHC class1 molecule which presents peptide to CD8 T cells. Current therapies treat inflammation but do not eliminate the cellular drivers of disease and only 40-60% of AxSpA patients achieve adequate disease control. Further, only 45% of PsA patients achieve minimal disease activity.
All News
CAR T is having its moment in rheumatology. But William Robinson’s presentation at ACR Convergence 2026 raised a question I find even more compelling: are we failing to eliminate the right B cells with therapies we already have?
It's been a while since we had a new urate lowering therapy for gout Pozdeutinurad = potent URAT1 inhibitor (think probenicid) -> blocks uric acid reabsorption Dramatic drop in uric acid by 1 month Small signal for +stone formation #ACR26 @RheumNow #ACRbest LB20 https://t.co/NqGghDiafE
#Dazodolibep #RCT in #SjD #CD40Li fusion protein no Fc 3 arms - 2 protocols ⬆️signs #ESSDAI>5. Entered >10 Other ⬆️#ESSPRI #Sjogren’s 1 or 2ndary (25%) 93%F -1.8 diff from PBO +results #ACRbest new Rx! #LB22 #ACR26 #ACRbest @RheumNow @ACRheum https://t.co/JJaDp0nCnM
